2013-01-29
Insufficient serum caspofungin levels in a paediatric patient on ECMO
Publication
Publication
Medical Mycology Case Reports , Volume 2 - Issue 1 p. 23- 24
Caspofungin, aechinocandin, is a relatively new lipophilic antifungal drug. Little is known concerning the pharmacokinetics of caspofungin in children. Extracorporeal membrane oxygenation (ECMO) allows prolonged cardiopulmonary support in patients with life-threatening respiratory or cardiac failure. Pharmacokinetics may be altered by ECMO. We describe the case of a paediatric patient on ECMO with severe pneumonia and sepsis, who had subtherapeutic exposure of caspofungin despite normal to high dosages of caspofungin. Therapeutic drug monitoring is warranted.
| Additional Metadata | |
|---|---|
| , , , , | |
| doi.org/10.1016/j.mmcr.2012.12.006, hdl.handle.net/1765/64923 | |
| Medical Mycology Case Reports | |
| Organisation | Department of Pediatrics |
|
Koch, B., Wildschut, E., de Goede, A., de Hoog, M., & Brüggemann, M. (2013). Insufficient serum caspofungin levels in a paediatric patient on ECMO. Medical Mycology Case Reports, 2(1), 23–24. doi:10.1016/j.mmcr.2012.12.006 |
|
